Eli Lilly LLY Ratios & Valuation
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Profitability | |||||
| Gross margin | 330.4%+7.3pp | 323.1%+9.8pp | 313.3%+10.6pp | 302.8%+3.6pp | |
| Net margin | 111.2%+31.3pp | 79.9%+6.5pp | 73.5%-9.5pp | 83%-4.9pp | |
| Returns | |||||
| Return on equity | 362.4%+101pp | 261.1%+43.6pp | 217.5%-65.3pp | 282.8%-126pp | |
| Return on invested capital | 130.3%+38.8pp | 91.6%+6.2pp | 85.4%-22.6pp | 108%-12.6pp | |
| Efficiency | |||||
| Asset turnover | 2.6×+0.1× | 2.5×+0.1× | 2.3×-0.1× | 2.4×+0.1× | |
| Liquidity | |||||
| Current ratio | 5.8×+0.9× | 4.9×+0.5× | 4.4×-0.1× | 4.5×-0.5× | |
| Leverage | |||||
| Debt-to-equity | 8×-0.8× | 8.8×+1.2× | 7.6×+0.7× | 6.9×-2.2× | |
| Net debt / EBITDA | 6.9×-2.7× | 9.6×+0.5× | 9.1×+2.2× | 6.9×+0.4× | |
| Per Share | |||||
| Book value per share | $93.79+54.5% | $60.70+23.8% | $49.04+14.9% | $42.67+29.3% | |
| Valuation | |||||
| Market capitalization | $3.09T+2.6% | $3.01T+70.2% | $1.77T+43.1% | $1.24T+39.9% | |
| Price / earnings | 201.1×-185× | 386.2×+64.4× | 321.8×+117× | 205.2×+55.4× | |
| Price / sales | 54.5×-20.9× | 75.4×+18.7× | 56.7×+14.2× | 42.6×+10.1× | |
| Price / book | 150.3×-69.3× | 219.5×+59.3× | 160.2×+31.8× | 128.4×+10.5× | |
| EV / EBITDA | 154.9×-124× | 278.9×+50.0× | 228.9×+70.6× | 158.3×+43.4× | |
| Dividend yield | 2.7%+0.3pp | 2.4%-1.3pp | 3.6%-0.7pp | 4.4%-1.0pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Eli Lilly's ratios come from?
- Every ratio is computed from Eli Lilly's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
